Thought Technology Ltd. Continues Its Tradition of Supporting the AAPB Conference with World-Class Biofeedback Solutions and a Poker-Themed Exhibitor Demo
MONTREAL, May 6, 2025 /PRNewswire/ -- Thought Technology Ltd., a global leader in biofeedback instrumentation, is proud to once again exhibit at the Association for Applied Psychophysiology and Biofeedback (AAPB) Annual Conference, taking place May 14-17, 2025 in San Diego.
Thought Tech
As a long-time supporter of AAPB's mission, Thought Technology remains dedicated to advancing the field of psychophysiology through innovative tools that empower professionals and individuals alike.
At this year's event, Thought Technology will spotlight how its products can be used in settings where group dynamics play a role, such as family therapy sessions, couples counselling and team building activities, providing a way to strengthen the group by harnessing each individual's physiology. They'll have a bit of fun with this concept on Saturday, May 17th, when they will host a Texas Hold'em themed exhibitor demo. This engaging demonstration will illustrate how one's physiology can reveal their thoughts and emotions.
While seasoned poker players rely on controlling their expressions and body language to keep opponents guessing, their physiology might tell a different story. The eVu-TPS sensor and BioGraph Infiniti Synergy Suite can track subtle changes in heart rate, skin conductance, and temperature—offering insight into the pressure players feel in real time. Even if they keep a perfect poker face, the physiological data could indicate signs of stress or excitement. The real challenge will be whether players can manage their autonomic responses as effectively as they control their outward expressions.
Additionally, on Wednesday, May 14, 2025, Thought Technology's Technical Support Director, Frank DeGregorio, will lead a pre-conference workshop on Patient Intervention through the Use of Biofeedback Trainings with a Variety of Physiological Peripherals, offering hands-on training in the use of their biofeedback instrumentation. This interactive session will feature practical demonstrations and expert guidance, equipping attendees—whether new to biofeedback or experienced practitioners—with the knowledge and skills to effectively implement Thought Technology's clinical solutions in their practice.
Conference attendees are invited to visit Thought Technology at booth #8 to experience live demonstrations of their range of products, test the equipment firsthand, and gain valuable insights into how they can make the most of these innovative tools for optimizing wellness and performance.
"For years, the AAPB Conference has provided an invaluable platform for collaboration, learning, and innovation, and we're honored to be part of this annual gathering once again," said Helen Mavros, Sales and Marketing Director at Thought Technology Ltd. "Our robust line of biofeedback solutions reflects our ongoing commitment to supporting practitioners and the clients they serve in harnessing the power of physiological awareness."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Reddy launches the #1 simulation training platform at CCW Las Vegas
LAS VEGAS, June 10, 2025 /PRNewswire/ -- Reddy, the AI coaching platform redefining how customer experience (CX) teams train and develop their agents, today announced the launch of their Reddy 2.0 at Customer Contact Week (CCW) Las Vegas. This marks Reddy's second year of sponsoring at the world's largest CX event, and the most advanced set of features ever released for simulation training across the industry. Reddy 2.0 introduces a major leap forward in enterprise training with fully automated simulation creation, enhanced cross-functional collaboration tools for L&D and QA teams, further security and compliance certifications, and a brand refresh that embodies the platform's vision: transforming customer service agents into high-performing all-stars. Agent Training in the AI Era While much of the industry has rushed toward automation, research has raised caution. A Salesforce study released this week found that AI automation of customer service drops to just a 35% success on any interactions that require more than one step to resolve. This comes on the heels of Klarna's recent announcement that their pivot to full AI automation needed to be scaled back in order to restore human agents to their support model. While working on solving the long-term challenge of creating the complex, multi-turn AI agents of tomorrow, Reddy has bridged the gap with automation of training for better human agents today. In conjunction with the launch of their new features, Reddy also today signed their largest partner to date with over 2K global agents, after having validated gains in new hire performance during an initial piloting period that resulted in a 38x return on investment. Reddy 2.0 Launch Reddy's new features and branding are all designed around connecting various teams within enterprise CX organizations, allowing them to work together more easily to create the highest impact training programs for agents. Automated Simulation Authoring – L&D teams can now generate tailored simulations entirely using AI, with the ability to drop in existing materials to create realistic sandboxes of their complex interactions and systems. Changes to training programs and SOPs can now take instant effect inside of simulations, with the ability to test, version and publish across large content teams. Enterprise Collaboration Suite – Reddy has developed custom-built Learning Management, Knowledge Base and Project Management Systems that all reside inside of the platform and integrate with other common tools. This allows teams to consolidate information and updates in one streamlined workflow, ensuring that agents are always armed with the most up-to-date processes and materials. AI Privacy and Security – This week, Reddy received their SOC 2 Type 2 certification to go along with their HIPAA certification and PCI compliance. Reddy prides itself on the ability to pair software with change management, and in working closely together with Infosec and Procurement teams to navigate evolving policies around Generative AI. "Reddy brings together every team inside the contact center — from L&D to QA to team leads — making it easier than ever to turn agents into all-stars," said Adam Levin, Reddy's CEO and Co-Founder. "Our new design represents those connections, with a dynamic arrow-based system symbolizing the connections we create inside of one platform, and the forward momentum that Reddy helps agents achieve. They're handling more calls with confidence, resolving complex issues at a higher rate, and delivering happier customers for the brand." See It in Action Attendees at CCW Las Vegas can visit Reddy at Booth #1400 to explore the solution and see live demonstrations of its AI coaching platform in action, or learn more at View original content to download multimedia: SOURCE Reddy
Forbes
2 hours ago
- Forbes
Cvent App May End Bad Conference Notes And Blurry Screen Photos
AI-driven text capture and summarization technology from Cvent can replace most traditional ... More conference note-taking. Picture this: You're sitting in a dimly lit conference room or convention ballroom, listening to a speaker who has something interesting to say. You are frantically scribbling notes while trying to photograph slides displayed on a distant screen. Later, back at your hotel, you're squinting at blurry photos and deciphering handwriting that looks like it was written during an earthquake. Sound familiar? This frustrating ritual is repeated millions of times at business events worldwide. The good news is that it may finally be obsolete thanks to a breakthrough from event technology company Cvent. Today, I saw a new product in use at their annual Cvent Connect conference in San Antonio. In a packed ballroom with thousands of attendees, the company demonstrated a major advance in conference note-taking. Cvent's new feature transforms the traditional note-taking experience through real-time speech transcription combined with intelligent content capture. Attendees can now see a live, accurate transcript of the speaker's words directly in the event app. Amazingly, there was virtually zero lag between spoken words and displayed text. Seeing the text appear as the words came out of the speakers's mouth seemed almost magical at first. Here's how it solves most of the note-taking problem: instead of frantically writing illegible script, attendees simply tap a button when they hear something worth remembering. The system automatically captures not just that moment, but a full minute of the speaker's words. "Instead of scribbling notes on a notepad, they're just clicking a button," explains McNeel Keenan, Cvent's VP of Product Management. "We capture the last 40 seconds, and since maybe that speaker hasn't finished their point yet, we're going to capture the next 20 seconds." Raw transcripts aren't particularly helpful buried in a phone app weeks later. That's where artificial intelligence transforms captured content into something genuinely useful. The system automatically generates concise summaries of each captured segment and creates descriptive labels, eliminating the need for attendees to organize their own notes. "We use AI to make it valuable for the attendee," Keenan notes. "We summarize what was in that minute and we give it a little label so they don't have to label their own notes." The company plans to expand the feature to automatically capture whatever appears on screen when attendees hit the "snapshot" button—potentially ending the epidemic of blurry PowerPoint photos forever. No more stretching to photograph slides from the back of the room, or missing the slide completely because your phone went to sleep. From an attendee experience perspective, Cvent's innovation addresses a classic friction point that most people considerd unavoidable. Conference note-taking has remained stubbornly analog, creating unnecessary effort and often disappointing results. Writing notes and taking screen photos while trying to absorb complex information is far from ideal. The cognitive load of simultaneously listening, writing, and photographing content often means missing important nuances or connections. By eliminating the mechanical aspects of most note-taking, the new system allows attendees to focus entirely on listening and engaging with content. The technology reduces the effort required while improving the quality of preserved information. Early implementation at Cvent Connect demonstrated impressive technical performance. The transcription accuracy appeared remarkably high, even in a large venue with ambient noise, and the response time was virtually instantaneous. "I was amazed at how fast it was," Keenan observed. "It was coming in like 2 to 300 milliseconds, right behind the speaker." Perhaps more importantly, the system requires no additional effort from speakers or event organizers. Unlike previous attempts at presentation transcription that required speakers to use unfamiliar software or upload materials in advance, this event app-based solution works with any presentation style or technology setup. The new technology will also simplify the dreaded 'summarize for the boss' or 'share the highlights with the team' phase of the event. As Keenan explains, "When people get back to their office, they don't need to send a big email to their boss justifying the dollars they spent. They can share the key takeaways, they can share with their colleagues, and hopefully that'll be the reason that they get to bring two other colleagues next year." It's easy to imagine the app or its output being used to further distill the notes into useful summaries, even podcast-like audio overviews to be shared or used to refresh one's memory. I'd personally feed them to a model like Claude to suggest applications for the ideas, identify quick wins, etc. While the immediate benefit focuses on attendee experience, the technology creates something potentially more valuable: unprecedented insight into what actually resonates with audiences during presentations. As a speaker, I know when I see lots of audience members raise their phones to capture one of my slides that I've said something that resonates. What I can't do is remember later which slides got the most interest, much less quantify that attention. With this app, every time someone taps to save content, they're essentially voting for that moment as particularly valuable or interesting. This creates a real-time feedback loop that conference organizers and speakers have never had access to before. This revealed preference data represents a significant advance over traditional post-event surveys, which suffer from poor response rates and recall bias. Instead sketchy reports from a few attendees about what they found valuable, organizers can see exactly which moments sparked enough interest to warrant saving. The real test will be adoption and refinement of the technology as it scales beyond Cvent's own events. But for anyone who has ever returned from a conference with a collection of illegible notes and unusable photos, the promise is clear: better technology can preserve more value with significantly less effort. In a follow-up article, I'll explore how this seemingly simple innovation could reshape conference programming and speaker selection through the unprecedented audience engagement data it generates.
Yahoo
2 hours ago
- Yahoo
Growth Hormone Deficiency Market to Register Incremental Growth at a CAGR of 5.7% During the Forecast Period (2025-2034)
The growth hormone deficiency market is expected to see expansion across the 7MM driven by the introduction of innovative therapies, including LUM-201 and SCO-240, among others. Furthermore, the rising prevalence of growth hormone deficiency, driven by improved diagnostics, higher survival rates of premature infants, increased pituitary disorders, and environmental factors like endocrine-disrupting chemicals, is expected to drive market growth for growth hormone replacement therapies. LAS VEGAS, June 10, 2025 /PRNewswire/ -- Growth hormone deficiency (GHD) is a rare condition resulting from inadequate secretion of growth hormone by the anterior pituitary gland. It can originate from birth, develop later in life, or have no known cause, underscoring the intricate mix of genetic, environmental, and diagnostic influences. Idiopathic cases are particularly difficult to address due to the absence of identifiable causes, revealing gaps in current understanding of the condition's underlying biology. According to DelveInsight, there were approximately 207,000 prevalent GHD cases across the 7MM in 2024, with around 165,000 diagnosed. This number is projected to increase by 2034. The United States accounted for the largest share of diagnosed prevalent cases in 2024, with roughly 70,000 cases—a figure expected to grow over the 2025–2034 forecast period. Current treatment options for GHD include approved therapies such as SOGROYA, SKYTROFA, and NGENLA. Standard treatment typically involves daily subcutaneous injections, which can be particularly burdensome for children, especially those with a fear of needles. Learn more about growth hormone deficiency treatment guidelines @ Growth Hormone Deficiency Treatment Market SOGROYA (somapacitan-beco) is a long-acting human growth hormone (hGH) analog that replicates the function of natural growth hormone. It's approved for children aged 2.5 years and older with growth failure due to insufficient endogenous GH and is also indicated as replacement therapy for adults with GHD. SOGROYA works by binding to a dimeric GH receptor on target cells, activating downstream signaling pathways, and producing effects largely mediated by liver-derived IGF-1. Key regulatory approvals include: FDA approval for adult GHD in August 2020 and for pediatric GHD in April 2023; EMA approval in March 2021; and PMDA approval in Japan for adult GHD in January 2021 and for pediatric growth issues in June 2023. SKYTROFA/TRANSCON hGH (lonapegsomatropin-tcgd) is a pegylated, long-acting hGH formulated for once-weekly subcutaneous administration. It's approved in both the US and EU for pediatric patients (aged ≥1 year, ≥11.5 kg) with growth failure due to inadequate GH levels. It binds to GH receptors, initiating intracellular signaling and delivering both direct (e.g., tissue and metabolic regulation) and indirect (via IGF-1) effects, including chondrocyte development, increased hepatic glucose production, protein synthesis, and fat breakdown. Regulatory milestones include FDA approval in August 2021 for pediatric GHD, EU approval in January 2022 for patients aged 3–18, and an sBLA accepted by the FDA in December 2024 for adult GHD, with a PDUFA decision expected in July 2025. NGENLA (somatrogon-ghla) is another long-acting hGH analog developed to address inadequate natural GH production. Approved for children aged 3 and above with growth failure, NGENLA distinguishes itself from daily-injection therapies like GENOTROPIN by offering once-weekly dosing through an adjustable delivery device. It binds GH receptors and activates STAT5b signaling, leading to elevated IGF-1 and promoting linear growth and metabolic effects. NGENLA is approved in the US, EU, and Japan for pediatric GHD and is undergoing global Phase III trials for adult GHD. Regulatory highlights include US FDA approval in June 2023, European Commission approval in February 2022, and PMDA approval in January 2022. In July 2024, OPKO Health entered into a USD 250 million non-dilutive note agreement with HealthCare Royalty, backed by profit-sharing proceeds from its 2014 global partnership with Pfizer. Find out more on FDA-approved growth hormone deficiency treatment @ Growth Hormone Deficiency Drugs Market Existing treatments for growth hormone deficiency typically involve subcutaneous injections, available in both daily and newer weekly formats. However, the need for daily administration can be particularly difficult for children, often resulting in low adherence. To address this issue and enhance patient compliance, researchers are developing long-acting and oral alternatives. Companies like Lumos Pharma and SCOHIA PHARMA are advancing their candidates through clinical trials, contributing to innovation in the growth hormone deficiency space and opening up substantial opportunities for market growth. Discover which therapies are expected to grab major growth hormone deficiency market share @ Growth Hormone Deficiency Therapy LUM-201 (ibutamoren), an oral small molecule developed by Lumos Pharma, functions as an agonist of the growth hormone secretagogue receptor to stimulate the natural pulsatile release of growth hormone (GH). This targeted approach supports its use in conditions requiring enhanced GH production. Clinical studies have shown that LUM-201 is both safe and consistently effective in promoting GH secretion. Notably, the Phase II OraGrowtH210 and OraGrowtH212 trials in children with pediatric growth hormone deficiency (PGHD) successfully met all primary and secondary endpoints, reinforcing the drug's therapeutic value. In 2017, LUM-201 was granted orphan drug designation (ODD) in both the US and EU for treating growth hormone deficiency, which provides development incentives. Data presented at the European Society for Paediatric Endocrinology conference in November 2024 demonstrated sustained growth over 24 months, affirming the effectiveness of its pulsatile secretion mechanism. In December 2024, Double Point Ventures acquired Lumos Pharma through a tender offer, paying USD 4.25 per share along with contingent value rights. SCO-240, from SCOHIA PHARMA, is an oral small molecule that selectively blocks Somatostatin Receptor 5 (SSTR5), a receptor involved in hormonal regulation. While the exact function of SSTR5 in humans remains under investigation, SCO-240 has shown encouraging results in enhancing GH secretion. In a Phase I clinical study, the drug triggered significant GH release without disrupting other pituitary hormones, underscoring the therapeutic potential of SSTR5 antagonism for GH-related conditions. The compound exhibited a strong safety profile, was well-tolerated, and is suitable for once-daily oral use. In June 2023, findings from the study were presented at the 96th Annual Congress of the Japan Endocrine Society, highlighting its promise in treating GH deficiency, female infertility, and alopecia. In February 2024, SCO-240 was selected for AMED's Orphan Drug Prior to Designation support program, securing funding for its continued development in PGHD. Discover more about drugs for growth hormone deficiency in development @ Growth Hormone Deficiency Clinical Trials The anticipated launch of these emerging therapies for growth hormone deficiency are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the growth hormone deficiency market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for growth hormone deficiency is expected to grow from USD 1.4 billion in the 7MM in 2024 at a significant 5.7% CAGR by 2034. This growth across the 7MM is expected to be fueled by the launch of novel therapies such as LUM-201 and SCO-240, among others. Additionally, the increasing prevalence, attributed to advancements in diagnostic capabilities, improved survival rates of premature infants, a rise in pituitary disorders, and environmental influences like endocrine-disrupting chemicals, is projected to boost the demand for growth hormone replacement therapies. DelveInsight's latest published market report, titled as Growth Hormone Deficiency Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the growth hormone deficiency country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The growth hormone deficiency market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Prevalent Cases of Growth Hormone Deficiency Total Diagnosed Prevalent Cases of Growth Hormone Deficiency Total Diagnosed Prevalent Cases of Pediatric Growth Hormone Deficiency Total Diagnosed Prevalent Cases of Adult Growth Hormone Deficiency Gender-specific Cases of Growth Hormone Deficiency Etiology-specific Cases of Growth Hormone Deficiency The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM growth hormone deficiency market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this growth hormone deficiency market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the growth hormone deficiency market. Also, stay abreast of the mitigating factors to improve your market position in the growth hormone deficiency therapeutic space. Related Reports Growth Hormone Deficiency Epidemiology Forecast Growth Hormone Deficiency Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted GHD epidemiology in the 7MM, i.e., the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan. Growth Hormone Deficiency Pipeline Growth Hormone Deficiency Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GHD companies, including Novo Nordisk, Ascendis Pharma, among others. Adult Growth Hormone Deficiency Market Adult Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key adult growth hormone deficiency companies, including Novo Nordisk, Ascendis Pharma, among others. Pediatric Growth Hormone Deficiency Market Pediatric Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pediatric growth hormone deficiency companies, including TJ Biopharma, Lumos Pharma, SCOHIA PHARMA, Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Melden Sie sich an, um Ihr Portfolio aufzurufen.
